Catalyst To Begin Second Phase 1 Study For CPP-115 - Quick Facts

(RTTNews) - Catalyst Pharmaceutical Partners, Inc. (CPRX) has begun a second Phase 1 study for its epilepsy drug CPP-115 and is scheduled to announce the results at the end of first quarter or early in the second quarter of 2015.

"Our preclinical experience with CPP-115 has demonstrated its potential for certain epilepsy indications, infantile spasms and other neurological diseases," said Chief Scientific Officer and COO, Steven Miller.

The Phase 1(b) trial, to be conducted in two parts, will test for the safety and tolerance of CPP-115, as well as for CNS side effects, and respiratory and cardiovascular safety.

Catalyst Pharma says CPP-115 inhibits GABA aminotransferase to raise brain GABA levels which reduce epileptogenesis - the process by which a brain develops epilepsy.